Form 8-K · Current report
West Pharmaceutical Services 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0000105770
- Accession no.
- 0000105770-26-000118
Summary
West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million, up 8.7% year over year with 11.9% organic growth, and adjusted-diluted EPS of $2.66, up 35.7%, led by its High-Value Product Components business. The company raised its full-year 2026 net sales guidance to $3.41–$3.42 billion and adjusted-diluted EPS guidance to $9.38–$9.48; CEO Michel Lagarde attributed the results to strong execution and operating margin expansion.
Key points
- Q3 2026 net sales were $874.5 million, up 8.7% reported and 11.9% organically; adjusted-diluted EPS of $2.66 rose 35.7%.
- Full-year 2026 net sales guidance was raised to $3.41–$3.42 billion from $3.345–$3.380 billion, and adjusted-diluted EPS guidance to $9.38–$9.48 from $8.85–$9.05.
- Full-year capital spending guidance was lowered to $215–$220 million from $250–$275 million.
- The board declared a fourth-quarter dividend of $0.26 per share, an 18% increase over the prior quarter's $0.22, and the company repurchased $231 million of stock in the quarter.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On October 29, 2026, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its third-quarter 2026 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Item 7.01 Regulation FD Disclosure. The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.